Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD123/CLL1 CAR-T Cell Therapy for Relapsed/Refractory AML
NCT03631576Phase 3Unknown
- Sponsor
- Fujian Medical University
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of CD123/CLL1 CAR-T Cells in acute myeloid leukemia (AML), sponsored by Fujian Medical University. Primary endpoint: Leukemia free survival at 1 year. Status: unknown.
02
Drugs
CD123/CLL1 CAR-T Cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03631576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631576.